PCSK9: A key factor modulating atherosclerosis

Journal of Atherosclerosis and Thrombosis

Volumn 22, Issue 3, 2015, Pages 221-230

  Li, Sha ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Atherosclerosis; Coronary artery disease; Hyperlipidemia; Proprotein convertase subtilisin kexin type 9

Indexed keywords

APOLIPOPROTEIN B; KEXIN TYPE 9; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN; PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME INHIBITION; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INJURY; LIPID METABOLISM; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ATHEROSCLEROSIS; HUMANS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84925344911     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.27615     Document Type: Review

References (73)

1. Mendis S, Chestnov O: The global burden of cardiovascular diseases: a challenge to improve. Curr Cardiol Rep, 2014; 16: 486
2. Wang JC, Bennett M: Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res, 2012; 111: 245-259
3. van Diepen JA, Berbee JF, Havekes LM, Rensen PC: Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis, 2013; 228: 306-315
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335: 1001-1009
5. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002; 360: 1623-1630
6. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, Santos RD, Verdejo J, Messig M, McPherson R, Seung KB, Tarasenko L: Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation, 2009; 120: 28-34
7. Urban D, Poss J, Bohm M, Laufs U: Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol, 2013; 62: 1401-1408
8. Wu NQ, Guo YL, Xu RX, Liu J, Zhu CG, Jiang LX, Li JJ: Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia: laboratory findings and response to lipid-lowering drugs. Clin Lab, 2013; 59: 901-907
9. Wu NQ, Li JJ: PCSK9 gene mutations and low-density lipoprotein cholesterol. Clin Chim Acta, 2014; 431:148- 153
10. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet, 2003; 34: 154-156
11. Lambert G, Charlton F, Rye KA, Piper DE: Molecular basis of PCSK9 function. Atherosclerosis, 2009; 203: 1-7
12. Lan H, Pang L, Smith MM, Levitan D, Ding W, Liu L, Shan L, Shah VV, Laverty M, Arreaza G, Zhang Q, Murgolo NJ, Hernandez M, Greene JR, Gustafson EL, Bayne ML, Davis HR, Hedrick JA: Proprotein convertase subtilisin/ kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells. J Cell Physiol, 2010; 224: 273-281
13. Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, Qing P, Wu NQ, Jiang LX, Li JJ: Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis, 2014; 234: 441-445
14. Norata GD, Tibolla G, Catapano AL: Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol, 2014; 54: 273-293
15. Weber C, Noels H: Atherosclerosis: current pathogenesis and therapeutic options. Nat Med, 2011; 17: 1410-1422
16. Kwon GP, Schroeder JL, Amar MJ, Remaley AT, Balaban RS: Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation, 2008; 117: 2919-2927
17. Sun P, Dwyer KM, Merz CN, Sun W, Johnson CA, Shircore AM, Dwyer JH: Blood pressure, LDL cholesterol, and intima-media thickness: a test of the "response to injury" hypothesis of atherosclerosis. Arterioscler Thromb Vasc Biol, 2000; 20: 2005-2010
18. Janis MT, Tarasov K, Ta HX, Suoniemi M, Ekroos K, Hurme R, Lehtimaki T, Paiva H, Kleber ME, Marz W, Prat A, Seidah NG, Laaksonen R: Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency. Atherosclerosis, 2013; 228: 380-385
19. Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL: Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis, 2012; 220: 381-386
20. Attie AD, Seidah NG: Dual regulation of the LDL receptor-- some clarity and new questions. Cell Metab, 2005; 1: 290-292
21. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S: Serum proprotein convertase subtilisin/ kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation, 2013; 127: 2403-2413
22. Maxwell KN, Breslow JL: Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A, 2004; 101: 7100-7105
23. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A: Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific lowdensity lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology, 2008; 48: 646- 654
24. Mayer G, Poirier S, Seidah NG: Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem, 2008; 283: 31791-31801
25. Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB: Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol, 2012; 32: 1585-1595
26. Sun XM, Eden ER, Tosi I, Neuwirth CK, Wile D, Naoumova RP, Soutar AK: Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet, 2005; 14: 1161-1169
27. Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, Krempf M: Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol, 2004; 24: 1448-1453
28. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG: The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem, 2008; 283: 2363-2372
29. Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG: Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One, 2013; 8: e64145
30. Levy E, Ben Djoudi Ouadda A, Spahis S, Sane AT, Garofalo C, Grenier E, Emonnot L, Yara S, Couture P, Beaulieu JF, Menard D, Seidah NG, Elchebly M: PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis, 2013; 227: 297-306
31. Le May C, Kourimate S, Langhi C, Chetiveaux M, Jarry A, Comera C, Collet X, Kuipers F, Krempf M, Cariou B, Costet P: Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol, 2009; 29: 684-690
32. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA: Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol, 2012; 59: 2344- 2353
33. Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C: Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun, 2008; 374: 341- 344
34. Tang Z, Jiang L, Peng J, Ren Z, Wei D, Wu C, Pan L, Jiang Z, Liu L: PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. Int J Mol Med, 2012; 30: 931-938
35. Li S, Zhu CG, Guo YL, Xu RX, Zhang Y, Sun J, Li JJ: The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease. J Atheroscler Thromb, 2014; [Epub ahead of print]
36. Ranheim T, Mattingsdal M, Lindvall JM, Holla OL, Berge KE, Kulseth MA, Leren TP: Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9. J Cell Physiol, 2008; 217: 459-467
37. Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, Florio A, Loria P: Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol, 2014; 20: 3410-3417
38. Labonte P, Begley S, Guevin C, Asselin MC, Nassoury N, Mayer G, Prat A, Seidah NG: PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology, 2009; 50: 17-24
39. Le Bras M, Roquilly A, Deckert V, Langhi C, Feuillet F, Sebille V, Mahe PJ, Bach K, Masson D, Lagrost L, Costet P, Asehnoune K, Cariou B: Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab, 2013; 98: E732-E736
40. van Poelgeest EP, Swart RM, Betjes MG, Moerland M, Weening JJ, Tessier Y, Hodges MR, Levin AA, Burggraaf J: Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis, 2013; 62: 796-800
41. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH: Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab, 2009; 94: 2537- 2543
42. Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, Davignon J, Lambert M: Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem, 2009; 55: 1637-1645
43. Cui Q, Ju X, Yang T, Zhang M, Tang W, Chen Q, Hu Y, Haas JV, Troutt JS, Pickard RT, Darling R, Konrad RJ, Zhou H, Cao G: Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis, 2010; 213: 632-636
44. Langhi C, Le May C, Gmyr V, Vandewalle B, Kerr-Conte J, Krempf M, Pattou F, Costet P, Cariou B: PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun, 2009; 390: 1288-1293
45. Mbikay M, Sirois F, Mayne J, Wang GS, Chen A, Dewpura T, Prat A, Seidah NG, Chretien M, Scott FW: PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett, 2010; 584: 701-706
46. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR: The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis, 2007; 193: 445-448
47. Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, Cianflone K, Seidah NG, Prat A: Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol, 2011; 31: 785-791
48. Sharotri V, Collier DM, Olson DR, Zhou R, Snyder PM: Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J Biol Chem, 2012; 287: 19266-19274
49. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg- Hansen A: PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol, 2010; 55: 2833-2842
50. Berge KE, Ose L, Leren TP: Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol, 2006; 26: 1094-1100
51. Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med, 2006; 354: 1264-1272
52. Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, Marais AD, van Heyningen C, Soutar AK: Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol, 2005; 25: 2654-2660
53. Davignon J, Dubuc G, Seidah NG: The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep, 2010; 12: 308-315
54. Roberts R: Genetics of coronary artery disease. Circ Res, 2014; 114: 1890-1903
55. Chen SN, Ballantyne CM, Gotto AM, Jr., Tan Y, Willerson JT, Marian AJ: A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol, 2005; 45: 1611-1619
56. Huijgen R, Fouchier SW, Denoun M, Hutten BA, Vissers MN, Lambert G, Kastelein JJ: Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. J Lipid Res, 2012; 53: 979-983
57. Lee CJ, Lee YH, Park SW, Kim KJ, Park S, Youn JC, Lee SH, Kang SM, Jang Y: Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism, 2013; 62: 845-850
58. Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, Qing P, Wu NQ, Li JJ: Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. Int J Cardiol, 2014
59. Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD: Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation, 2012; 125: 1979-1987
60. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Jr., Ridker PM, Kastelein JJ: Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA, 2012; 307: 1302-1309
61. Werner C, Hoffmann MM, Winkler K, Bohm M, Laufs U: Risk prediction with proprotein convertase subtilisin/ kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol, 2014; 62: 94-102
62. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A: Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis- regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol, 2004; 24: 1454-1459
63. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD: Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A, 2005; 102: 5374-5379
64. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ: High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res, 2010; 51: 2714-2721
65. Catapano AL, Papadopoulos N: The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclero- sis, 2013; 228: 18-28
66. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK: The PCSK9 decade. J Lipid Res, 2012; 53: 2515- 2524
67. Jia YJ, Xu RX, Sun J, Tang Y, Li JJ: Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats. J Transl Med, 2014; 12: 103
68. Dong B, Wu M, Li H, Kraemer FB, Adeli K, Seidah NG, Park SW, Liu J: Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res, 2010; 51: 1486- 1495
69. Noto D, Cefalu AB, Averna MR: Beyond statins: new lipid lowering strategies to reduce cardiovascular risk. Curr Atheroscler Rep, 2014; 16: 414
70. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA: Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol, 2014; 63: 1278-1288
71. Shen L, Peng H, Xu D, Zhao S: The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors. Pharmacol Res, 2013; 73: 27-34
72. Marais DA, Blom DJ, Petrides F, Goueffic Y, Lambert G: Proprotein convertase subtilisin/kexin type 9 inhibition. Curr Opin Lipidol, 2012; 23: 511-517
73. Seidah NG, Awan Z, Chretien M, Mbikay M: PCSK9: A Key Modulator of Cardiovascular Health. Circ Res, 2014; 114: 1022-1036